Survival of the fittest doesn't apply. Shocking!

Natalia

http://www.world-science.net/othernews/100901_superbugs

*Drug-resistant germs found to help their brethren through the attack*

Sept. 1, 2010
Courtesy of Howard Hughes Medical Institute
and World Science <http://www.world-science.net> staff

*Confronting at­tack by an­ti­bi­otics, some bac­te­ria help each oth­er out---and un­for­tu­nately for us, they're bet­ter off for it, re­search­ers have found.

Though a small frac­tion of pathogens in a col­o­ny may have evolved the abil­ity to re­sist a drug or class of drugs, these "su­per bugs" were found to help their more vul­ner­a­ble peers by over-pro­duc­ing a drug-fighting sub­stance.

Pre­vail­ing wis­dom held that an­ti­bi­ot­ic re­sistance works only on an in­di­vid­ual lev­el: a bac­te­ri­um ac­quires a muta­t­ion that con­fers pro­tec­tion against a drug, al­low­ing it to sur­vive and re­pro­duce. Even­tu­al­ly, as vul­ner­a­ble bac­te­ria die, the mu­tan­t's stronger prog­e­ny re­pop­u­late the col­o­ny. This basically reflects how evolution is believed to work in all species: mem­bers that are "fit­ter" or bet­ter adapt­ed to pre­vail­ing con­di­tions spread their genes through the po­pu­lation at the ex­pense of other mem­bers.

But the new stu­dy, to ap­pear in the Sept. 2 is­sue of the re­search jour­nal / Na­ture/, in­di­cates there are al­so popula­t­ion-wide changes in the bac­te­ri­al com­mun­ity at work. Faced with an on­slaught of an­ti­bi­otics, re­sistant / Esch­e­rich­i­chia coli/ mi­crobes pro­duce---at an en­er­gy cost to them­selves---a pro­tein mol­e­cule that seeps in­to the com­munal broth and trig­gers a slew of pro­tec­tive mech­a­nisms in their non-re­sistant neigh­bors.

The study comes from re­search­ers at the How­ard Hughes Med­i­cal In­sti­tute in Chevy Chase, Md.

In the past few years, the rise of "su­per bugs" such as me­thi­cillin-re­sistant / Staph­y­lo­coc­cus au­re­us/, or MRSA, has had hos­pi­tals and med­i­cal pro­fes­sion­als scram­bling to fend off a pub­lic health dis­as­ter. The new find­ings could help ex­plain why re­sistance has been so hard to curb, the re­search­ers say.

The in­sti­tute's James J. Col­lins and col­leagues at Bos­ton Uni­vers­ity grew bac­te­ria in a biore­ac­tor---a large, capped glass ves­sel with many ex­tend­ed arms that al­low re­search­ers pre­cise con­trol over what the bugs are ex­posed to. "It kind of looks like a com­po­nent of a moon­shine fac­to­ry out in the back­woods," Col­lins said.

In­ter­est­ed in how ge­net­ic­ally iden­ti­cal /E. coli/ ac­quire muta­t­ions that con­fer re­sistance, the re­search­ers trick­led the an­ti­bi­ot­ic nor­floxacin in­to the biore­ac­tor. As they upped the bugs' ex­po­sure, the sci­en­tists per­i­od­ic­ally re­moved sam­ples of bac­te­ria and meas­ured the min­i­mum strength of drug that stops growth of the bug.

"That's when we were stopped in our tracks," Col­lins said. To their sur­prise, the re­search­ers found that the popula­t­ion as a whole was much more drug-re­sistant than in­di­vid­ual sam­ples. Less than one in a hun­dred in­di­vid­uals were typ­ic­ally drug-re­sistant.

The team then an­a­lyzed the pro­teins made by re­sistant bac­te­ria in the pres­ence of nor­floxacin, and found that a com­pound called tryp­to­phanase was par­tic­u­larly abun­dant. Tryp­to­phanase breaks down a bi­o­log­i­cal mol­e­cule, the ami­no ac­id tryp­to­phan, in­to smaller bits. One of the prod­ucts of this re­ac­tion is in­dole, a sig­nal­ing mol­e­cule that / E. coli/ pro­duces un­der cer­tain stress­ful con­di­tions.

In­dole turns out to of­fer bac­te­ria two kinds of pro­tec­tion against nor­floxacin, ac­cord­ing to Col­lins' group. One is to turn on cel­lu­lar machines that pump the an­ti­bi­ot­ic out of the cell, as if ex­pel­ling a poi­son. In­dole al­so turns on chem­i­cal pro­cesses that pro­tect the cell from ox­i­da­tive stress, a chem­i­cal im­bal­ance that leads to the build up tox­ic mol­e­cules called free rad­i­cals. A few years ago, Col­lins's team re­ported that an­ti­bi­otics tend to work by pum­mel­ing bugs with free rad­i­cals. "Here we're see­ing that in­dole is damp­en­ing that---turn­ing on the sprin­klers for the fire re­sult­ing from the an­ti­bi­otics," he said.

By com­par­ing the growth of bac­te­ria, the re­search­ers found that the mu­tants pro­duce in­dole at a sig­nif­i­cant cost to them­selves. "They don't grow as well as they could, be­cause they're pro­duc­ing in­dole for eve­ry­body else," Col­lins said.

Such al­tru­is­tic be­hav­ior---which ap­pears in spe­cies through­out the an­i­mal king­dom, in­clud­ing hu­man­s---p­re­sents a well-known par­a­dox for ev­o­lu­tion­ary bi­ol­o­gists: if ev­o­lu­tion fa­vors the fit­test, why would an in­di­vid­ual sac­ri­fice its own fit­ness for the rest of the group?

Col­lins said his find­ings bol­ster the "kin se­lec­tion" the­o­ry---for­malized in the 1960s by the Brit­ish ev­o­lu­tion­ary bi­ol­o­gist W.D. Hamil­ton---that said that or­gan­isms may be­have al­tru­is­tic­ally to­ward oth­ers that share their genes. By protecting their own gene pool, they promote the spread of their genes indirectly, even if they them­selves suffer or die in the pro­cess. This prin­ciple could have been at work in the "chari­table" /E. coli,/ since they were helping mem­bers of their own popula­t­ion.

"We are plan­ning to ex­plore wheth­er si­m­i­lar strate­gies are used by oth­er bac­te­ri­al spe­cies," Col­lins added.

Col­lins thinks the study is most di­rectly per­ti­nent to pub­lic health. The re­search­ers found that the same popula­t­ion-wide pro­tec­tion oc­curs when bugs are ex­posed to oth­er kinds of an­ti­bi­otics. What's more, many types of bac­te­ria pro­duce in­dole, sug­gest­ing that a si­m­i­lar co­op­er­a­tive pro­cess may hap­pen in a host of bac­te­ri­al spe­cies.

Fu­ture re­search on an­ti­bi­otics might well fo­cus on tar­get­ing the in­dole path­way as a means to block bugs' abil­ity to share re­sistance, Col­lins said. More broad­ly, the work high­lights the press­ing need for in­vest­ment in new an­ti­bi­ot­ic de­vel­op­ment. "The chance that we'll have new and dan­ger­ous su­per bugs emerg­ing is quite high, and I'm wor­ried that our ar­se­nal of an­ti­bi­otics is dwindling," Col­lins said. "We have time to re­spond now, but we need a move­ment backed by po­lit­i­cal will to ex­pand an­ti­bi­ot­ic re­search and de­vel­op­ment."**
*

P.S. 1) The movement of the human from shared chemical communication to the verbal communication of the individual may be the point of fragmentation of our species. We constantly mask our senses with additional "chemical smells" or "air cleaners" or various and sundry items in our day-to-day lives (many of which are chronic poisons) creating a maelstrom of information for our bodies to interpret. This could throw the bodies defenses into play creating reactions such as asthma or other chronic reactions that are becoming more prominent in our societies... As with the small, so with the large. I believe that verbal communication can keep the individual separated from the group as a whole and more often serves ego needs more effectively for certain individuals in the group but, reduces the chances of survival of the group as a whole and therefore society at large. Verbal communication can be twisted; chemical communication...not so easy, unless masked with external scents.

2) If the "indole" molecule is used by a bacterium to fend off an onslaught of poisons, what do our own body's cells do to protect themselves from those same drugs? If we throw into the mix of anti-bacterials an indole blocker, what reaction occurs in our own cells and our own immune responses?

My only experience with the indole molecule is as part of the plant growth hormone indoleacetic acid. Finding indole being utilized in the above manner by single celled bacterium is, in my humble opinion, troubling as it once more indicates the closeness with which ALL life on this planet is related. Throwing poisons at something (no matter how small) poisons the rest of life; whether those poisons are chemical or verbal.


Darryl

_______________________________________________
Futurework mailing list
[email protected]
https://lists.uwaterloo.ca/mailman/listinfo/futurework

Reply via email to